Collectively, these results show that PRMT5 controls breast cancer cell growth through epigenetic silencing of WNT/β‐CATENIN pathway antagonists, DKK1 and DKK3, resulting in up‐regulation of WNT/β‐CATENIN proliferative signalling. Here, PRMT5 is linked to breast cancer.